{
    "organizations": [],
    "uuid": "966edeb1df2e193935728cfc7ced364ee3dbd6ee",
    "author": "",
    "url": "https://www.reuters.com/article/brief-acelrx-resubmits-new-drug-applicat/brief-acelrx-resubmits-new-drug-application-for-dsuvia-idUSFWN1SG0QY",
    "ord_in_thread": 0,
    "title": "BRIEF-Acelrx Resubmits New Drug Application For Dsuvia",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 9, 2018 / 11:22 AM / Updated 10 minutes ago BRIEF-Acelrx Resubmits New Drug Application For Dsuvia Reuters Staff\nMay 9 (Reuters) - AcelRx Pharmaceuticals Inc: * ACELRX RESUBMITS NEW DRUG APPLICATION FOR DSUVIA\n* ACELRX PHARMACEUTICALS INC - EXPECTS A SIX-MONTH REVIEW BY FDA WITH A PROJECTED PDUFA DATE IN Q4 2018\n* ACELRX PHARMACEUTICALS INC - ANTICIPATES THAT FDA WILL ACKNOWLEDGE ACCEPTANCE OF NDA WITHIN 30 CALENDAR DAYS OF RESUBMISSION DATE\n* ACELRX PHARMACEUTICALS INC - POTENTIAL MARKETING AUTHORIZATION FROM EMA IS EXPECTED IN Q3 OF 2018 FOR DSUVIA ",
    "published": "2018-05-09T14:20:00.000+03:00",
    "crawled": "2018-05-09T14:40:43.009+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "updated",
        "minute",
        "ago",
        "resubmits",
        "new",
        "drug",
        "application",
        "dsuvia",
        "reuters",
        "staff",
        "may",
        "reuters",
        "acelrx",
        "pharmaceutical",
        "inc",
        "acelrx",
        "resubmits",
        "new",
        "drug",
        "application",
        "dsuvia",
        "acelrx",
        "pharmaceutical",
        "inc",
        "expects",
        "review",
        "fda",
        "projected",
        "pdufa",
        "date",
        "q4",
        "acelrx",
        "pharmaceutical",
        "inc",
        "anticipates",
        "fda",
        "acknowledge",
        "acceptance",
        "nda",
        "within",
        "calendar",
        "day",
        "resubmission",
        "date",
        "acelrx",
        "pharmaceutical",
        "inc",
        "potential",
        "marketing",
        "authorization",
        "ema",
        "expected",
        "q3",
        "dsuvia"
    ]
}